儿童大环内酯类耐药重症肺炎支原体肺炎的临床特征及危险因素分析

doi:10.12372/jcp.2024.24e0026

Abstract

Abstract:

Objective To explore the clinical features and risk factors of macrolide-resistant severe Mycoplasma pneumoniae pneumonia (SMPP) in children. Methods The clinical data of children with macrolide-resistant Mycoplasma pneumoniae pneumonia (MPP) who were hospitalized in the Department of Pediatric Respiratory Medicine from March to September 2023 were retrospectively analyzed. According to the severity of the disease, the patients were divided into macrolide-resistant severe group and macrolide-resistant non-severe group. The clinical characteristics of the two groups were compared, and the risk factors affecting SMPP were analyzed. Results A total of 224 children with macrolide resistant MPP were included, including 132 in the severe group (65 boys and 67 girls), with a median age of 7.0 (5.0-9.0) years. There were 92 patients in the macrolide-resistant non-severe group, 46 boys and 46 girls, with a median age of 7.0 (5.0-9.0) years. The results of binary logistic regression analysis showed that prolonged fever time, increased D-dimer level and lung consolidation were independent risk factors for predicting the occurrence of macrolide-resistant SMPP (P<0.05), while higher lactate dehydrogenase and IgE levels may be correlated with the occurrence of macrolide-resistant SMPP (P<0.05). ROC curve analysis showed that the duration of fever, lactate dehydrogenase and D-dimer had moderate diagnostic value in predicting the occurrence of macrolide-resistant SMPP (AUC>0.8, P<0.05). All patients with macrolide-resistant Mycoplasma pneumoniae pneumonia were cured and discharged after treatment. The length of hospital stay in the macrolide-resistant severe group was 7.0 (6.0-9.0) days, significantly longer than that in macrolide-resistant non-severe group [6.0 (5.0-7.0) days] (P<0.01). The hospitalization cost in the macrolide-resistant severe group was 12283 (10836-15012) yuan, which was significantly higher than that in the macrolide-resistant non-severe group [9769 (8756-11642) yuan], and the differences were statistically significant (P<0.01). Conclusions Children with macrolide-resistant SMPP experienced more prolonged fevers and hospital stays, markedly elevated inflammatory markers, and severe alterations in lung imaging, all of which raised the financial strain on their families.

Key words: Mycoplasma pneumoniae, macrolide-resistant, severe pneumonia, risk factor, child

CHEN Mengxue, LI Jingyang, YANG Fen, TIAN Ye, LI Jing, DING Guodong. Clinical features and risk factors of macrolide-resistant severe Mycoplasma pneumoniae pneumonia in children[J].Journal of Clinical Pediatrics, 2024, 42(3): 187-192.

Figures/Tables 5

References 26

[1]	Liu TY, Lee WJ, Tsai CM, et al. Serum lactate dehydrogenase isoenzymes 4 plus 5 is a better biomarker than total lactate dehydrogenase for refractory Mycoplasma pneumoniae pneumonia in children[J]. Pediatr Neonatol, 2018, 59(5): 501-506. doi: 10.1016/j.pedneo.2017.12.008
[2]	Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016[J]. Epidemiol Infect, 2019, 147: e192. doi: 10.1017/S0950268819000839
[3]	闫超, 孙红妹, 赵汉青, 等. 北京地区10年间住院患儿肺炎支原体感染流行特征分析[J]. 中华实用儿科临床杂志, 2019, 34(16): 1211-1214.
[4]	Yan C, Xue G, Zhao H, et al. Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in children[J]. Pediatr Pulmonol, 2019, 54(7): 1012-1021. doi: 10.1002/ppul.v54.7
[5]	陈佳怡, 尚云晓. 耐大环内酯类药物的儿童肺炎支原体肺炎的研究进展[J]. 国际儿科学杂志, 2020, 47(5): 335-339.
[6]	王亨, 刘金荣, 赵顺英. 儿童重症肺炎支原体肺炎的诊治进展[J]. 中华实用儿科临床杂志, 2023, 38(11) : 842-845.
[7]	Zhou Y, Shan Y, Cui Y, et al. Characteristics and outcome of severe Mycoplasma pneumoniae pneumonia admitted to PICU in Shanghai: a retrospective cohort study[J]. Crit Care Explor, 2021, 3(3): e0366. doi: 10.1097/CCE.0000000000000366
[8]	胡亚美, 江载芳. 诸福棠实用儿科学[M]. 第8版. 北京: 人民卫生出版社, 2015: 1280-1282.
[9]	中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 中国合理用药探索, 2023, 20(3): 16-24.
[10]	中华人民共和国国家健康委员会, 国家中医药局. 儿童社区获得性肺炎诊疗规范(2019年版)[J]. 中华临床感染病杂志, 2019, 12(1): 6-13.
[11]	Kim K, Jung S, Kim M, et al. Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis[J]. JAMA Netw Open, 2022, 5(7): e2220949. doi: 10.1001/jamanetworkopen.2022.20949
[12]	Chen YC, Hsu WY, Chang TH. Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia[J]. Emerg Infect Dis, 2020, 26(7): 1382-1391. doi: 10.3201/eid2607.200017
[13]	Yan C, Xue G, Zhao H, et al. Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in children[J]. Pediatric Pulmonology, 2019, 54(7): 1012-1021. doi: 10.1002/ppul.v54.7
[14]	Lee KL, Lee CM, Yang TL, et al. Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019 [J]. J Formos Med Assoc, 2021, 120(1 Pt 1):281-291. doi: 10.1016/j.jfma.2020.08.018
[15]	刘莉萍, 杨泽玉, 王玉, 等. 儿童重症肺炎支原体肺炎的临床特征及相关危险因素分析[J]. 中国小儿急救医学, 2023, 30(6): 451-456.
[16]	Poddighe D, Comi EV, Brambilla I, et al. Increased total serum immunoglobulin E in children developing Mycoplasma pneumoniae-related extra-pulmonary diseases[J]. Iran J Allergy Asthma Immunol, 2018, 17(5): 490-496.
[17]	Zhu Y, Luo Y, Li L, et al. Immune response plays a role in Mycoplasma pneumoniae pneumonia[J]. Front Immunol, 2023, 14: 1189647. doi: 10.3389/fimmu.2023.1189647
[18]	国家卫生计生委合理用药专家委员会儿童用药专业组. 中国儿童肺炎支原体感染实验室诊断规范和临床实践专家共识(2019年)[J]. 中华儿科杂志, 2020, 58(5): 366-373.
[19]	Zheng Y, Hua L, Zhao Q, et al. The level of D-Dimer is positively correlated with the severity of Mycoplasma pneumoniae pneumonia in children[J]. Front Cell Infect Microbiol, 2021, 11: 687391. doi: 10.3389/fcimb.2021.687391
[20]	Qiu J, Ge J, Cao L. D-dimer: the risk factor of children's severe Mycoplasma pneumoniae pneumonia[J]. Front Pediatr, 2022, 10: 828437. doi: 10.3389/fped.2022.828437
[21]	张敏. 儿童重症肺炎支原体肺炎的临床特点及影像学表现分析[J]. 中国CT和MRI杂志, 2020, 18(2): 37-40.
[22]	Cho YJ, Han MS, Kim WS, et al. Correlation between chest radiographic findings and clinical features in hospitalized children with Mycoplasma pneumoniae pneumonia[J]. PLoS One, 2019, 14(8): e0219463. doi: 10.1371/journal.pone.0219463
[23]	Guo H, He Z, Li M, et al. Imbalance of peripheral blood Th17 and Treg responses in children with refractory Mycoplasma pneumoniae pneumonia[J]. Infect Chemother, 2016, 22(3): 162-166.
[24]	刘峰. 肺炎支原体肺炎与预后相关的临床指标[J]. 临床儿科杂志, 2022, 40(4): 247-251.
[25]	赵顺英, 陈志敏, 刘瀚旻, 等. 国家卫生健康委员会《儿童肺炎支原体肺炎诊治指南(2023 年版)》重点解读[J]. 临床儿科杂志, 2023, 41(3): 224-228.
[26]	Zhou LL, Li Y, Xu ZF, et al. Increased total serum immunoglobulin E is likely to cause complications of Mycoplasma pneumoniae pneumonia in children[J]. Front Cell Infect Microbiol, 2021, 11: 783635. doi: 10.3389/fcimb.2021.783635

项目	耐药重症组(n=132)	耐药非重症组(n=92)	统计量	P
年龄[M(P₂₅~P₇₅)]/岁	7.0(5.0~9.0)	7.0(5.0~9.0)	Z=0.04	0.971
男性[n(%)]	65(49.2)	46(50.0)	χ²=0.01	0.911
发热时间[M(P₂₅~P₇₅)]/d	8.0(7.0~9.0)	5.0(4.0~6.0)	Z=9.45	<0.001
白细胞计数[M(P₂₅~P₇₅)]×10⁹·L^-1	7.5(5.9~9.0)	6.6(5.3~8.1)	Z=1.78	0.076
血小板计数[M(P₂₅~P₇₅)]×10⁹·L^-1	319.5(252.8~382.5)	309.5(255.3~397.5)	Z=0.37	0.710
C-反应蛋白[M(P₂₅~P₇₅)]/mg·L^-1	14.0(6.3~27.0)	5.0(3.0~13.0)	Z=4.94	<0.001
降钙素原[M(P₂₅~P₇₅)]/ng·mL^-1	0.2(0.1~0.4)	0.1(0.1~0.3)	Z=3.59	<0.001
乳酸脱氢酶[M(P₂₅~P₇₅)]/U·L^-1	352.0(325.0~402.0)	285.5(259.8~317.0)	Z=8.94	<0.001
铁蛋白[M(P₂₅~P₇₅)]/μg·L^-1	120.0(89.0~164.8)	92.4(59.6~123.5)	Z=4.10	<0.001
红细胞沉降率[M(P₂₅~P₇₅)]/mm·h^-1	31.0(23.3~42.8)	24.0(17.0~33.0)	Z=3.23	0.001
肌钙蛋白Ⅰ[M(P₂₅~P₇₅)]/ng·mL^-1	0.002(0.002~0.003)	0.002(0.002~0.002)	Z=2.09	0.036
丙氨酸氨基转移酶[M(P₂₅~P₇₅)]/U·L^-1	16.0(13.0~23.0)	14.5(12.0~19.8)	Z=2.15	0.032
D-二聚体[M(P₂₅~P₇₅)]/mg·L^-1	0.8(0.6~1.1)	0.5(0.4~0.6)	Z=7.77	<0.001
IgE[M(P₂₅~P₇₅)]/IU·mL^-1	168.0(53.3~410.0)	80.4(31.2~229.0)	Z=2.85	0.004

项目	耐药重症组(n=132)	耐药非重症组(n=92)	统计量	P
胸腔积液	15(11.4)	0(0)	-	0.001¹⁾
肺实变	92(69.7)	41(44.6)	χ²=14.20	<0.001
病变范围			χ²=22.88	<0.001
斑片状或云絮状影	33(25.0)	52(56.5)
大片状阴影	99(75.0)	40(43.5)

变量	偏回归系数	标准误	χ²值	P	OR(95%CI)
IgE	0.00	0.00	7.47	0.006	1.00(1.00~1.01)
乳酸脱氢酶	0.03	0.01	14.82	<0.001	1.03(1.02~1.05)
发热时间	1.11	0.25	19.71	<0.001	3.04(1.86~4.97)
肺实变	1.60	0.65	6.07	0.014	4.97(1.39~17.79)
D-二聚体	4.37	1.34	10.57	0.001	79.15(5.68~1 103.49)
常量	-21.28	3.69	33.31	<0.001	-

变量	最佳阈值	AUC(95%CI)	P	灵敏度/%	特异度/%	约登指数
IgE/IU·mL^-1	128.0	0.60(0.52~0.68)	0.021	55.9	63.3	0.19
D-二聚体/mg·L^-1	0.6	0.81(0.74~0.87)	<0.001	73.9	78.5	0.52
乳酸脱氢酶/U·L^-1	324.5	0.85(0.80~0.91)	<0.001	74.8	86.1	0.61
发热时间/d	6.5	0.88(0.83~0.93)	<0.001	81.1	81.0	0.62

Clinical features and risk factors of macrolide-resistant severe Mycoplasma pneumoniae pneumonia in children

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 26

Related Articles 15

Metrics

Comments

Recommended 0

[1]	YIN Yong, CHEN Jiande. Diagnosis and treatment philosophy and practice of macrolide-resistant Mycoplasma pneumoniae pneumonia in children [J]. Journal of Clinical Pediatrics, 2024, 42(3): 177-181.
[2]	GU Yutong, YANG Fen, YE Jianmin, HUA Li, LI Jing, DING Guodong. Macrolide resistance in hospitalized children with Mycoplasma pneumoniae pneumonia and its clinical diagnosis and treatment [J]. Journal of Clinical Pediatrics, 2024, 42(3): 182-186.
[3]	JI Xiaodan, ZHAO Shunying. Clinical characteristics analysis of Mycoplasma pneumoniae necrotizing pneumonia and bacterial necrotizing pneumonia [J]. Journal of Clinical Pediatrics, 2024, 42(3): 193-197.
[4]	BIAN Zhaonan, ZHA Xinyi, ZHANG Xi, CHEN Xuting, CHEN Yanru, XU Min, ZHANG Yonghong, QIAN Jihong. Pathogenic characteristics of neonatal sepsis and influence factors of gram-negative bacterial infection: based on a 5-year retrospective clinical study [J]. Journal of Clinical Pediatrics, 2024, 42(3): 204-210.
[5]	CHEN Shicai, DUAN Lifen, SUN Ying, SHAO Juwei, LI Qiong, LUO Mingying, REN Junjun, ZHANG Yunqian. Correlation between cognitive function and electroclinical characteristics of benign childhood epilepsy with centrotemporal spikes [J]. Journal of Clinical Pediatrics, 2024, 42(3): 211-217.
[6]	WANG Yingjie, CHEN Zhiwei, MAI Yumiao, SUN Pan, JING Zhaohe, DONG Pengpeng, LIU Jian. Allogeneic hematopoietic stem cell transplantation for treatment of dyskeratosis congenita: a report of 3 cases and literature review [J]. Journal of Clinical Pediatrics, 2024, 42(3): 243-248.
[7]	ZHANG Ying, XU Hongmei. Clinical and etiological analysis of adenovirus infection and liver damage in children [J]. Journal of Clinical Pediatrics, 2024, 42(3): 259-263.
[8]	LI Niu, LI Lei, CHEN Huiwen, WANG Jian, ZHANG Hao. Construction of the Shanghai children's rare disease registration database and summary of phased data [J]. Journal of Clinical Pediatrics, 2024, 42(2): 102-109.
[9]	ZHAO Shuai, MA Ang, LUO Shuying, XIA Songchen, HAO Chanjuan, LI Wei, WEI Haiyan, ZHANG Yaodong. Clinical characteristics of 20 rare diseases in children based on specific disease data [J]. Journal of Clinical Pediatrics, 2024, 42(2): 110-115.
[10]	ZHOU Yang, WU Yali, DING Yan. Clinical characteristics and genotype analysis of adenosine deaminase 2 (ADA2) deficiency in China: a report of three cases [J]. Journal of Clinical Pediatrics, 2024, 42(2): 116-120.
[11]	SUN Ruonan, LI Bohan, ZHENG Defei, ZHAO Xiaying, LIN Ziyun, HU Yixin, GAO Li, GAO Jing, LI Jie, LU Jun, XIAO Peifang, PAN Jian, LING Jing, FANG Fang, HU Shaoyan. Factors related to bronchiolitis obliterans syndrome in pediatric patients survived longer than 100 days after hematopoietic stem cell transplantation [J]. Journal of Clinical Pediatrics, 2024, 42(2): 139-145.
[12]	LIANG Huan, ZHANG Huiwen. Diagnosis of a child with Duchenne muscular dystrophy using optical genome mapping [J]. Journal of Clinical Pediatrics, 2024, 42(2): 146-150.
[13]	YAO Qianghua, WANG Yingchao, WANG Dao, LIU Yufeng. Analysis of risk factors for early death of acute promyelocytic leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(1): 53-57.
[14]	JIN Mei, LIU Jing, LIU Kang, ZHAO Libo, ZHAO Ziwei, SUN Suzhen. Characteristics of neurofilament light chain levels in cerebrospinal fluid of Guillain-Barre syndrome in children [J]. Journal of Clinical Pediatrics, 2024, 42(1): 58-62.
[15]	GENG Tian, YU Zhongsu, ZHOU Xixi, LIU Bo, ZHANG Huihua, LI Zhongyue. Analysis of eradication effect and influencing factors of triple therapy of Helicobacter pylori in children [J]. Journal of Clinical Pediatrics, 2024, 42(1): 63-69.